| A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer (NCT04730349) | Bristol-Myers Squibb | 2021-06-03 |
| A Study Evaluating Quality of Life for Participants With Atrial Fibrillation (AF) Following a Bleed (EQUAL-AF) (NCT05044533) | Bristol-Myers Squibb | 2021-05-31 |
| A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants (NCT04882150) | Bristol-Myers Squibb | 2021-05-27 |
| A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (NCT04895709) | Bristol-Myers Squibb | 2021-05-27 |
| A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (NCT04810078) | Bristol-Myers Squibb | 2021-05-21 |
| A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis (NCT04877990) | Bristol-Myers Squibb | 2021-05-07 |
| A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy (NCT04151563) | Bristol-Myers Squibb | 2021-04-15 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants (NCT04763226) | Bristol-Myers Squibb | 2021-04-14 |
| A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan (NCT05027061) | Bristol-Myers Squibb | 2021-04-02 |
| A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235 (NCT04464577) | Bristol-Myers Squibb | 2021-04-01 |
| Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (NCT04495010) | Bristol-Myers Squibb | 2021-03-31 |
| A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT (NCT04766892) | Bristol-Myers Squibb | 2021-03-30 |
| A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis (NCT04772079) | Bristol-Myers Squibb | 2021-03-23 |
| A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) (NCT04817007) | Bristol-Myers Squibb | 2021-03-22 |
| A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer (NCT04702880) | Bristol-Myers Squibb | 2021-03-17 |
| Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH) (NCT04267393) | Bristol-Myers Squibb | 2021-03-17 |
| A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants (NCT06133049) | Bristol-Myers Squibb | 2021-03-16 |
| A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis (NCT04613518) | Bristol-Myers Squibb | 2021-03-15 |
| A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®) (NCT05335031) | Bristol-Myers Squibb | 2021-03-03 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants (NCT04736134) | Bristol-Myers Squibb | 2021-03-03 |
| A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease (NCT04766476) | Bristol-Myers Squibb | 2021-02-24 |
| A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (NCT04623775) | Bristol-Myers Squibb | 2021-02-17 |
| BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome (NCT04684654) | Bristol-Myers Squibb | 2021-02-16 |
| A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors (NCT04567615) | Bristol-Myers Squibb | 2021-02-04 |
| An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (NCT03770299) | Bristol-Myers Squibb | 2021-01-15 |
| A Study of Adjuvant Melanoma Stakeholder Treatment Preferences (NCT05115006) | Bristol-Myers Squibb | 2021-01-07 |
| A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer (NCT04794010) | Bristol-Myers Squibb | 2020-12-22 |
| Effect of BMS-986165 on the Blood Levels of Metformin (NCT04671953) | Bristol-Myers Squibb | 2020-12-18 |
| A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India (NCT04513522) | Bristol-Myers Squibb | 2020-12-17 |
| A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan (NCT05161325) | Bristol-Myers Squibb | 2020-12-15 |
| A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment (NCT04634149) | Bristol-Myers Squibb | 2020-11-23 |
| Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise (NCT04472494) | Bristol-Myers Squibb | 2020-10-14 |
| A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) (NCT04446650) | Bristol-Myers Squibb | 2020-10-12 |
| A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy (NCT04500535) | Bristol-Myers Squibb | 2020-09-28 |
| A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants (NCT04550195) | Bristol-Myers Squibb | 2020-09-17 |
| A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer (NCT04340193) | Bristol-Myers Squibb | 2020-09-14 |
| A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread (NCT04540705) | Bristol-Myers Squibb | 2020-09-11 |
| A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma (NCT04088500) | Bristol-Myers Squibb | 2020-09-03 |
| A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France (NCT04550247) | Bristol-Myers Squibb | 2020-09-02 |
| A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants (NCT04305899) | Bristol-Myers Squibb | 2020-08-31 |
| A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus (NCT04493541) | Bristol-Myers Squibb | 2020-08-26 |
| Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities (NCT04572893) | Bristol-Myers Squibb | 2020-08-04 |
| Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants (NCT04515628) | Bristol-Myers Squibb | 2020-08-02 |
| A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis (NCT04308681) | Bristol-Myers Squibb | 2020-07-29 |
| Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe (NCT04493567) | Bristol-Myers Squibb | 2020-07-29 |
| Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants (NCT04470778) | Bristol-Myers Squibb | 2020-07-20 |
| Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors (NCT04349267) | Bristol-Myers Squibb | 2020-07-14 |
| A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole) (NCT04468815) | Bristol-Myers Squibb | 2020-07-10 |
| A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial Fibrillation (NCT05232643) | Bristol-Myers Squibb | 2020-07-09 |
| Participant Reported Outcomes and Treatment Experiences in Kidney Cancer (NCT04472663) | Bristol-Myers Squibb | 2020-07-06 |
| A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy (NCT04349072) | Bristol-Myers Squibb | 2020-07-06 |
| A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (NCT04311710) | Bristol-Myers Squibb | 2020-06-25 |
| A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom (NCT04936399) | Bristol-Myers Squibb | 2020-06-25 |
| Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants (NCT04444050) | Bristol-Myers Squibb | 2020-06-23 |
| Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants (NCT04301310) | Bristol-Myers Squibb | 2020-03-09 |
| A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function (NCT04237831) | Bristol-Myers Squibb | 2020-02-26 |
| A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time (NCT04263350) | Bristol-Myers Squibb | 2020-02-26 |
| Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants (NCT04269356) | Bristol-Myers Squibb | 2020-02-18 |
| Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants (NCT04249284) | Bristol-Myers Squibb | 2020-02-06 |
| A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer (NCT04209114) | Bristol-Myers Squibb | 2020-02-05 |
| A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment (NCT04225936) | Bristol-Myers Squibb | 2020-01-16 |
| A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (NCT04149574) | Bristol-Myers Squibb | 2020-01-15 |
| A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers (NCT04209699) | Bristol-Myers Squibb | 2019-12-27 |
| A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy (NCT05432622) | Bristol-Myers Squibb | 2019-12-19 |
| A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke (NCT04126486) | Bristol-Myers Squibb | 2019-12-17 |
| An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia (NCT04146324) | Bristol-Myers Squibb | 2019-12-12 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants (NCT04154800) | Bristol-Myers Squibb | 2019-12-06 |
| An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea (NCT04167462) | Bristol-Myers Squibb | 2019-11-25 |
| Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (NCT04109066) | Bristol-Myers Squibb | 2019-11-18 |
| A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants (NCT04175925) | Bristol-Myers Squibb | 2019-11-15 |
| A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer (NCT04025879) | Bristol-Myers Squibb | 2019-11-05 |
| An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (NCT03704077) | Bristol-Myers Squibb | 2019-10-31 |
| Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (NCT04099251) | Bristol-Myers Squibb | 2019-10-28 |
| A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer (NCT04075604) | Bristol-Myers Squibb | 2019-10-18 |
| A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (NCT04026412) | Bristol-Myers Squibb | 2019-10-08 |
| A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin (NCT04124003) | Bristol-Myers Squibb | 2019-10-08 |
| The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants (NCT04113668) | Bristol-Myers Squibb | 2019-10-01 |
| A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327 (NCT04069143) | Bristol-Myers Squibb | 2019-10-01 |
| A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab (NCT04112498) | Bristol-Myers Squibb | 2019-10-01 |
| A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (NCT04039607) | Bristol-Myers Squibb | 2019-09-30 |
| A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults (NCT04116632) | Bristol-Myers Squibb | 2019-09-30 |
| A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan (NCT04043975) | Bristol-Myers Squibb | 2019-09-19 |
| A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and Methotrexate (NCT05421299) | Bristol-Myers Squibb | 2019-09-16 |
| An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition. (NCT04086719) | Bristol-Myers Squibb | 2019-09-12 |
| An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers (NCT03994601) | Bristol-Myers Squibb | 2019-09-06 |
| A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets (NCT04065932) | Bristol-Myers Squibb | 2019-08-22 |
| A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants (NCT04055506) | Bristol-Myers Squibb | 2019-08-14 |
| A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR) (NCT04196452) | Bristol-Myers Squibb | 2019-08-12 |
| Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (NCT04036435) | Bristol-Myers Squibb | 2019-08-12 |
| Pan Tumor Rollover Study (NCT03899155) | Bristol-Myers Squibb | 2019-08-09 |
| A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (NCT04008030) | Bristol-Myers Squibb | 2019-08-05 |
| A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal (NCT05168436) | Bristol-Myers Squibb | 2019-08-05 |
| A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants (NCT04016753) | Bristol-Myers Squibb | 2019-08-05 |
| Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil (NCT04039373) | Bristol-Myers Squibb | 2019-07-22 |
| A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants (NCT04082741) | Bristol-Myers Squibb | 2019-07-18 |
| An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis (NCT03943147) | Bristol-Myers Squibb | 2019-07-15 |
| Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis (NCT03934216) | Bristol-Myers Squibb | 2019-07-01 |
| A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register (NCT05413044) | Bristol-Myers Squibb | 2019-07-01 |
| A Study to Assess the Effectiveness of an Atrial Fibrillation (AF) Risk Prediction Algorithm and Diagnostic Test in Identifying Patients With AF. (NCT04045639) | Bristol-Myers Squibb | 2019-06-30 |
| A Study of Nivolumab in Patients With Head and Neck Cancer. (NCT04050761) | Bristol-Myers Squibb | 2019-06-26 |